News
all
press releases
Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?
Zacks
Blueprint Medicines Stock Lands Several Downgrades After Sanofi’s Buyout Deal, But Retail Bulls Keep The Faith
Analysts revised price targets near the deal’s $129-per-share valuation.
Stocktwits
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
Zacks
Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies
Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.
Stocktwits

Advertisement|Remove ads.